Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report

José Angelo Lauletta Lindoso[1],[2], Carlos Henrique Valente Moreira[2],[3],[6], Beatriz Julieta Celeste[3], Luiza Keiko Matsuka Oyafuso[3], Pedro Moreira Folegatti[4] and Eduard Evert Zijlstra[5]

[1]. Laboratório de Soroepidemiologia (LIM 38), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.
[2]. Instituto de Infectologia Emilio Ribas, São Paulo, SP, Brasil.
[3]. Instituto de Medicina Tropical da Universidade de São Paulo, São Paulo, SP, Brasil.
[4]. The Jenner Institute, Nuffield Department of Medicine, University of Oxford, United Kingdom.
[5]. Rotterdam Centre for Tropical Medicine, Rotterdam, the Netherlands.
[6]. Laboratório de Parasitologia (LIM 46), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.

Abstract

Visceral leishmaniasis is common in Brazil and is caused by Leishmania (Leishmania) infantum/chagasi. Post-kala-azar dermal leishmaniasis frequently follows visceral leishmaniasis caused by L. donovani, and para-kala-azar dermal leishmaniasis refers to an uncommon presentation wherein it occurs simultaneously along with visceral leishmaniasis. While post-kala-azar dermal leishmaniasis only occurs occasionally in L. infantum/chagasi infections, it frequently occurs in patients with concomitant immunosuppression (HIV co-infection). Here, we describe the first case of para-kala-azar dermal leishmaniasis in Brazil. It is important to raise awareness of post- and para-kala-azar dermal leishmaniasis in L. infantum endemic areas as these patients may contribute to visceral leishmaniasis transmission.

Keywords: Visceral leishmaniasis. Dermal leishmaniasis. Leishmania infantum.

INTRODUCTION

Visceral leishmaniasis (VL) is common in South America and 90% of cases occur in Brazil. The main vector is Lutzomyia longipalpis and canines function as the main reservoir. In recent years, the disease has spread to all regions and emerged in urban areas. In Latin America, cutaneous manifestations in leishmaniasis are related to Leishmania from the subgenus Viannia; however, there are reports of cutaneous lesions similar to those observed in post-kala-azar dermal leishmaniasis (PKDL), caused by Leishmania infantum, mainly in human immunodeficiency virus (HIV)-infected patients. In addition, L. infantum can cause atypical cutaneous leishmaniasis in Central America unrelated to VL. Here, we describe an HIV-negative patient with VL with an unusual clinical course and outcome, in which a relapse of VL was accompanied by a PKDL-like skin rash.

CASE REPORT

A 36-year-old farmer presented at the Public General Hospital in Santos City because of fever. He was born in the city of Sao Vicente in South-East Brazil. He reported that he had worked in Joao Pessoa, Paraiba, North-East Brazil, an endemic area for VL, from 2000 to 2006. During that time, his dog became ill and died. He first presented in November 2006 with a long history of daily fever, headache, general weakness, and dizziness, and he reported to have lost weight (18 kg in the last 3 months). His weight at the time of admission was 53 kg. Hepatosplenomegaly was noted on physical examination. VL was suspected and confirmed by a bone marrow aspirate that showed Leishmania amastigotes. HIV test results were negative.

He was treated with meglumine antimoniate (Glucantime) intramuscular (IM) in a dose of 20 mg/kg/day for 28 days with positive clinical response.

He did not return for follow-up but presented in January 2008 with a (clinically diagnosed) relapse and was treated with two cycles of Abelcet (amphotericin B lipid complex) daily (1 mg/kg/day) for 20 days followed by two cycles of glucantime (20 mg/kg/day for 28 days) combined with Abelcet (1 mg/kg/day). In March 2008, he was admitted to the Institute of Infectology Emilio Ribas at Sao Paulo with fever and hepatosplenomegaly; a second relapse of VL was suspected.
Anti-<i>leishmania</i> antibodies were demonstrated in the immunofluorescence test (immunoglobulin (Ig)G 1:160) and enzyme-linked immunosorbent assay (ELISA) (IgG 1: 1280); the Montenegro test results were negative. He was treated according to the National Guidelines for treatment of VL with liposomal amphotericin B (LAmb) (3 mg/kg once daily for 7 days) and exhibited a positive clinical response.

Five months later, he developed diarrhea and vomiting and he had lost 5 kg of weight. On physical examination, he was dehydrated, and his weight was 48 kg. In addition, on the skin of the chest and abdomen, erythematous macules and papules (diameter 0.5–1.0 cm) were noted (<strong>Figure 1A</strong> and <strong>Figure 1B</strong>). He was re-admitted to the hospital and received intravenous (IV) fluid replacement. A bone marrow aspirate showed numerous <i>Leishmania</i> amastigotes; in addition, a skin biopsy demonstrated an inflammatory process characterized by numerous small, oval, plasmacytoid structures indicative of infection by <i>Leishmania</i> sp. Additionally, on the surface, the epidermis was thin, with fibrosis of the papillary dermis.

The immunofluorescence test for <i>Leishmania</i> showed an IgG titer of 1:64, whereas in the ELISA, the IgG titer was 1:320. Treatment was initiated with amphotericin B deoxycholate (50 mg/day for 4 days), followed by LAmb (3 mg/kg for 10 days), with positive response.

Laboratory investigations showed negative results for antibodies against HIV, human T-cell lymphotropic virus (HTLV)-1 and -2, <i>T. cruzi</i>, and hepatitis A. IgG antibodies were found against cytomegalovirus (CMV) and toxoplasma. The IgM ELISA results for schistosomiasis were positive. Immunological assessment revealed the following: cluster of differentiation CD4+ count, 777 cells/mm³; CD8+ count, 633 cells/mm³; and CD4/CD8 ratio: 1.23. Lymphocyte proliferation tests showed proliferation on stimulation with <i>Leishmania</i> and <i>Toxoplasma</i> antigen. Proliferative responses against mitogens were normal.

Secondary prophylaxis was suggested, but he did not return for follow-up. Ten months later, he presented with fever and cervical lymphadenopathy that initiated 20 days earlier; a cervical lymph node biopsy showed its architecture replaced by hard granulomas without central necrosis and rare giant cells. In addition, in the macrophages, a large amount of <i>Leishmania</i> sp. was observed.

There was no evidence for hepatosplenomegaly. He was treated with LAmb 4 mg/kg/day for 7 days and secondary prophylaxis was initiated with pentavalent antimonial (IV or IM) (850 mg every 28 days), after which he remained well during 9 months of follow-up. To better characterize treatment response observed after treatment and secondary prophylaxis, we measured anti-<i>Leishmania</i> antibody titers using ELISA and indirect immunofluorescence (IFI), using <i>Leishmania major</i>-like total antigen; decreases in titers were observed 6 and 16 months post-treatment (<strong>Figure 2</strong>).

**DISCUSSION**

In this patient, inflammatory processes associated with fibrosis from papillary dermis with the presence of <i>Leishmania</i> was observed in cutaneous lesions. In macular lesions of PKDL, chronic inflammation is characterized by infiltrates of lymphocytes and macrophages containing <i>Leishmania</i> amastigotes.
of histiocytes, lymphocytes, and a few plasma cells, and Leishmania is also observed\textsuperscript{10}. However, there are no consistent infiltrates in PKDL lesions. The clinical manifestations of PKDL are immunologically mediated with features of a Th2 response in the skin and a systemic Th1 response, resulting in skin abnormalities in patients who are otherwise well without features of systemic leishmanial infection\textsuperscript{5-10,11}. In this patient, the clinical progression from visceral disease with subsequent relapses to para-kala-azar dermal leishmaniasis and later isolated (post-kala-azar) lymphadenopathy without obvious clinical evidence of visceral disease suggests a similarly developing, but abnormal and inadequate systemic immune response\textsuperscript{11,13}. In immunosuppressed patients, in particular those who are HIV infected, relapses are common, as some degree of developing antileishmanial immunity is needed to prevent a relapse of VL. With each relapse, the treatment becomes more difficult\textsuperscript{5}. This patient had a similar clinical syndrome, which justified the decision for maintenance treatment that to date seemed to be successful. There is no consensus regarding the preferred regimen; single-dose administration of pentavalent antimonial, Lamb (AmBisome ©) or pentamidine has been used, often in cycles of 3–4 weeks.

This case illustrates the need for follow-up of patients with VL, in particular to monitor for PKDL or para-kala-azar dermal leishmaniasis as experience elsewhere indicates that as the rash often remains unnoticed and self-cures, these patients often do not report to the clinic and may play a role in transmission.

Conflict of interest
The authors declare that there is no conflict of interest.

REFERENCES